Among the hedge funds and asset managers with concentrated exposure to specialty pharmaceutical companies, Armistice Capital, Baker Bros. Advisors, and RTW Investments appear together across multiple shareholder registers, suggesting shared interest in drug developers targeting high unmet medical needs. Armistice Capital manages more than $7 billion and maintains a portfolio weighted toward healthcare, while Baker Bros. and RTW bring their own long-established expertise in biotech and life sciences investing.

The three funds appear alongside one another in the institutional holders lists of companies including PTC Therapeutics and Travere Therapeutics, where rare-disease drug pipelines have drawn sustained attention from active managers. Vanguard Group and BlackRock hold larger positions in these same stocks through passive index mandates, while Driehaus Capital Management and Wellington Management round out the active management presence alongside Armistice, Baker Bros., and RTW.

PTC Therapeutics shows Armistice with roughly 5.43 million shares representing 6.86% of shares outstanding. Wellington Management increased its stake in PTC by approximately 13% in a recent quarter, while RTW Investments holds a position representing approximately 9.4% of shares outstanding, making RTW the third-largest institutional holder. Vanguard Group, with approximately 10.9%, holds the largest block. Travere Therapeutics, developing treatments for Alport syndrome and other rare kidney conditions, similarly shows Armistice with approximately 8.9 million shares alongside Baker Bros., Driehaus, and State Street as fellow institutional holders.

The overlap between Armistice Capital, Baker Bros. Advisors, and RTW Investments across these holdings illustrates a pattern common among healthcare-focused institutional managers: independent analysis frequently produces similar conclusions when evaluating drug pipelines with identifiable regulatory milestones. For market observers, the concentration of specialist fund ownership in the same names can indicate where active capital is most concentrated ahead of potential catalysts, though it does not necessarily imply coordination among holders.